Aptevo Therapeutics Inc. announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon. The Company plans to initiate pre-clinical studies this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.808 USD | -2.42% | 0.00% | 0.00% |
05-08 | Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.3M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- APVO Stock
- News Aptevo Therapeutics Inc.
- Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors